Mariner
ALNY icon

Mariner’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mariner’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.43M Sell
28,021
-1,927
-6% -$581K 0.01% 817
2026
Q1 		$9.91M Sell
29,948
-12,495
-29% -$4.25M 0.01% 753
2025
Q4 		$16.9M Buy
42,443
+16,111
+61% +$7.13M 0.02% 501
2025
Q3 		$12M Buy
26,332
+11,259
+75% +$4.58M 0.02% 568
2025
Q2 		$4.91M Buy
15,073
+190
+1% +$52.6K 0.01% 863
2025
Q1 		$4.02M Buy
14,883
+1,217
+9% +$313K 0.01% 903
2024
Q4 		$3.22M Buy
13,666
+1,947
+17% +$512K 0.01% 980
2024
Q3 		$3.22M Buy
11,719
+3,832
+49% +$998K 0.01% 955
2024
Q2 		$1.92M Buy
7,887
+993
+14% +$157K ﹤0.01% 1133
2024
Q1 		$1.03M Sell
6,894
-217
-3% -$36.2K ﹤0.01% 1478
2023
Q4 		$1.36M Sell
7,111
-7,070
-50% -$1.2M ﹤0.01% 1245
2023
Q3 		$2.51M Sell
14,181
-3,654
-20% -$697K 0.01% 888
2023
Q2 		$3.39M Sell
17,835
-1,531
-8% -$304K 0.01% 785
2023
Q1 		$3.88M Sell
19,366
-6,298
-25% -$1.32M 0.01% 716
2022
Q4 		$6.1M Sell
25,664
-780
-3% -$166K 0.02% 537
2022
Q3 		$5.29M Buy
+26,444
New +$5.04M 0.02% 497

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mariner's ALNY Position: Q2 2026 in Review

Mariner reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.4% in Q2 2026, selling an estimated $581K and leaving 28,021 shares worth $8.43M. The position accounts for 0.01% of the portfolio, ranked #817.

Mariner first reported a position in ALNY in Q3 2022 and has held it in 16 quarters since. The position peaked at $16.9M in Q4 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Mariner held 28,021 shares of Alnylam Pharmaceuticals worth $8.43M as of Q2 2026.
  • Mariner sold 1,927 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $581K.
  • Alnylam Pharmaceuticals made up 0.01% of Mariner's portfolio in Q2 2026, its #817 holding.
  • Mariner first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Mariner's Alnylam Pharmaceuticals position peaked at $16.9M in Q4 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.